Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
Therapy Name | SL-701 |
Synonyms | |
Therapy Description |
SL-701 is an immunotherapy that stimulates anti-tumor immune responses against tumor expressing IL13 receptor alpha-2, EphrinA2 and Survivin (J Clin Oncol 36, 2018 (suppl; abstr 2058)). |
Drug Name | Trade Name | Synonyms | Drug Classes | Drug Description |
---|---|---|---|---|
SL-701 | SL 701|SL701 | SL-701 is an immunotherapy that stimulates anti-tumor immune responses against tumor expressing IL13 receptor alpha-2, EphrinA2 and Survivin (J Clin Oncol 36, 2018 (suppl; abstr 2058)). |
Molecular Profile | Indication/Tumor Type | Response Type | Therapy Name | Approval Status | Evidence Type | Efficacy Evidence | References |
---|
Clinical Trial | Phase | Therapies | Title | Recruitment Status | Covered Countries | Other Countries |
---|---|---|---|---|---|---|
NCT02078648 | Phase Ib/II | SL-701 Poly ICLC Bevacizumab | Safety and Efficacy Study of SL-701, a Glioma-Associated Antigen Vaccine To Treat Recurrent Glioblastoma Multiforme | Completed | USA | 0 |